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ABSTRACT 
Prulifloxacin is a chemotherapeutic antibiotic of Fluor quinolone drug used to treat a various urinary tract infections. It has short half-life, 
makes the sustained release (SR) forms extremely advantageous. Sustained release tablets results in increased bioavailability. The purpose of 
the present study was to develop a sustain release matrix drug delivery system (SR) containing Prulifloxacin as a model drug by using various 
proportions of polymers such as HPMC E15, HPMC K15. The sustained release formulations of Prulifloxacin were prepared by direct 
compression method. Optimization of formulation was done by studying effect of drug to polymer ratio on drug release. FT-IR studies indicated 
absence of any interaction between Prulifloxacin, polymers (HPMC E15 and HPMC K15) and excipients. Ten formulations were prepared and 
Formulation F8 possesses good drug release property. The tablets were also evaluated for its hardness, friability and other In-vitro evaluation 
tests. All parameters complied with IP limits. Drug release was diffusion controlled and followed Zero order kinetics. Non-Fickian diffusion was 
the drug release mechanism for all the tablets formulated. 
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INTRODUCTION 
Sustained release dosage forms are designed to release a 
drug at a predetermined rate by maintaining a constant drug 
level for a specific period of time with minimum side effects. 
The basic rationale of sustained release drug delivery system 
optimizes the biopharmaceutical, pharmacokinetic and 
pharmacodynamics properties of a drug in such a way that 
its utility is maximized, side-effects are reduced and 
cure/treatment of the disease is achieved. Oral sustained 
release (SR) products provide an advantage over 
conventional dosage forms by optimizing bio-pharmaceutics, 
pharmacokinetics and pharmacodynamics properties of 
drugs in such a way that it reduce dosing frequency to an 
extent that once daily dose is sufficient for penetration, 
polymer swelling, drug dissolution, drug diffusion and Matrix 
erosion . The materials most widely used in preparing matrix 
systems include both hydrophilic and hydrophobic 
polymers1. 
Sustain release system includes any drug delivery systems 
that achieves slow release of drug over prolong period of 
time. Matrix tablets are considered to be the commercially 
feasible sustained action dosage forms that involve the least 
processing variables, utilize the conventional facilities and 
accommodate large doses of drug. There remains an interest 
in developing novel formulations that allow for sustained the 
drug release using readily available, inexpensive excipient by 
matrix based formulation. During the last two decades there 
has been remarkable increase in interest in sustained release 
drug delivery system. This has been due to various factors 
like the prohibitive cost of developing new drug entities, 
expiration of existing international patients, discovery of 
new polymeric materials suitable for prolonging the drug 
release, and the improvement in therapeutic efficiency and 
safety achieved by these delivery systems2.  
MATERIALS:  
Prulifloxacin was obtained as gift sample from DR.Reddys 
Laboratory, Hyderabad, other Chemicals like 
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Microcrystalline cellulose from SD Fine Chemicals Ltd., 
Mumbai, Magnesium Stearate and Talc were procured from 
Nice Chemicals Pvt. Ltd., Cochin, Polymers like HPMC E15, 
HPMC K15 were procured from S.Kant.Health Care Ltd., 
Gujarat and all other chemicals used for this study was 
analytical grade. 
METHODS: 
Compatibility studies 
The compatibility of drugs and excipients used under 
experimental condition were studied. The study was 
performed by taking 2 mg sample in 200 mg KBr (Bruker 
spectrum-100). The scanning range was 600 to 4000 cm-1 
and the resolution was 1cm-1. This spectral analysis was 
employed to check the compatibility of drugs with the 
excipients used5. 
Pre-Compression Characteristics 
The pre-compression characteristics like angle of repose, 
bulk density, tapped density Hauser’s ratio, Carr’s index, 
Scale of Flow ability were determined and tabulated in the 
table no 3. 
Angle of Repose: 
The angle of repose of powder mix was determined by the 
funnel-method. The accurately weighed granules were taken 
in a funnel. The height of the funnel was adjusted to a height 
of 2 cm in such a manner that the tip of the funnel just 
touched the apex of the heap of the granules. The granules 
were allowed to flow through the funnel freely onto the 
surface. The diameter of the powder cone measured and 
angle of repose was calculated using the following equation. 
Tan θ = h/r 
Where h and r are the height and radius of the powder cone, 
θ is the angle of repose. 
Angle of repose values less than 25, 25-30, 30-40, and more 
than 40 indicates excellent, good, passable, and poor flow 
properties respectively3, 7. 
 
 
Bulk density: 
Both loose bulk density (LBD) and tapped bulk density (TBD) 
were determined. A quantity of 2 g of powder from each 
formula, previously lightly shaken to break any agglomerates 
formed, was introduced into a 10ml measuring cylinder. 
After the initial volume was observed, the cylinder was 
allowed to fall under its own weight onto a hard surface from 
the height of 2.5 cm at 2 second intervals. The tapping was 
continued until no further change in volume was noted. LBD 
and TBD were calculated using the following formula4, 5. 
LBD = weight of the powder/volume of the packing      
 TBD = weight of the powder/tapped volume of the packing. 
Compressibility index: 
The compressibility index of the granules was determined 
by Carr’s Compressibility index.  
Carr’s index (%) = [(TBD-LBD) * 100] / TBD 
Where, LBD: Weight of the powder/volume of the packing. 
TBD:  Weight of the powder/Tapped volume of the packing. 
Hausner’s ratio: 
Hausner’s ratio can be determined by the following 
equation5, 
Hausner’s ratio = TBD / LBD  
Where, TBD -Tapped bulk densities & LBD- Loose bulk 
densities 
Formulation Prulifloxacin Matrix Tablets 
All the formulations were prepared by direct compression 
method using HPMC E15, HPMC K15 polymers in various 
ratios and other excipients microcrystalline cellulose, 
Magnesium Stearate and talc are used. Prulifloxacin and all 
other ingredients were individually passed through sieve  
60. All the ingredients were mixed thoroughly by triturating 
up to 15 min. The powder mixture was lubricated with 
magnesium stearate and talc. 
 
Table 1: Formulation of Prulifloxacin Matrix Tablets 
Ingredients (mg)    F1    F2   F3   F4   F5  F6   F7   F8   F9 
Prulifloxacin 200 200 200 200 200 200 200 200 200 
HPMC E15   100 200 300     -     -    -  150 200 100 
HPMC K15     -     -     -   100 200 300 150 100 200 
MCC 330 230 130 330 230 130 130 130 130 
Mg stearate    10 10 10 10 10 10 10 10 10 
Talc     10 10 10 10 10 10 10 10 10 
Total weight   650 650 650 650 650 650 650 650 650  
 
Post-Compression Characteristics 
The post-compression characteristics like Weight Variation, 
Thickness, Hardness, and Friability were determined and 
tabulated in the table no 4. 
 
Thickness and Diameter: 
Control of physical dimension of the tablet such as thickness 
and diameter is essential for consumer acceptance and 
tablet uniformity. The thickness and diameter of the tablet 
was measured using Vernier calipers. It is measured in mm6. 
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Tablet hardness: 
Tablet hardness of the tablets for shipping or breakage 
under conditions of storage, transportation and handling 
depends on hardness which was determined using 
Monsanto hardness tester. For each formulation, the 
hardness of 10 tablets was determined. The tablet was held 
along its oblong axis in between the two jaws of the tester. 
At this point, reading should be zero kg/ cm2. Then constant 
force was applied by rotating the knob until the tablet 
fractured. The value at this point was noted in kg/cm27, 8. 
Weight variation: 
This is an important In-process quality control test to be 
checked frequently (every half an hour). Corrections were 
made during the compression of tablets. Any variation in the 
weight of tablet (for any reason) leads to either under 
medication or overdose. So, every tablet in each batch 
should have a uniform weight. 20 tablets were weighed 
individually.  Average weight was calculated from the total 
weight of all tablets.  The individual weights were compared 
with the average weight. The percentage difference in the 
weight variation should be within the permissible limits 
(7.5%). The percent deviation was calculated using the 
following formula. The limits are mentioned in the below 
table as per Indian pharmacopoeia (I.P) 9, 10. 
Friability Test: 
For each formulation, 6 tablets were weighed. The tablets 
were placed in a Friabilator (Roche Friabilator) and 
subjected to 100 rotations in 4 minutes at 25 rpm. The 
tablets were then reweighed. The friability was calculated as 
the percentage weight loss.11, 12 
%Friability = (Loss in weight/Initial weight) x 100 
In vitro drug release studies13, 14:  
Drug release studies were conducted using USP-22 
dissolution apparatus-2, paddle type (Lab India) at a 
rotational speed of 50 rpm at 37±0.5º. The dissolution media 
used were 900 ml of 0.1 mol / l HCl for first 2 h followed by 
pH 6.8 phosphate buffer solutions for 22h. Sink condition 
was maintained for the whole experiment. Samples (10 ml) 
were withdrawn at regular intervals and the same volume of 
pre-warmed (37±0.5º) fresh dissolution medium was 
replaced to maintain the volume constant. The samples 
withdrawn were filtered through a 0.45 μ membrane filter 
and the drug content in each sample was analyzed after 
suitable dilution with a UV spectrophotometer (Shimadzu 
UV-1700) at 276nm. The dissolution test was performed in 
triplicate. Drug dissolved at specified time periods was 
plotted as cumulative percent release versus time (h) curve 
and results obtained were tabulated in table no 5 . 
RESULTS AND DISCUSSION 
Table 2: Calibration curve for Estimation of Prulifloxacin 
S.NO Concentration(µg/ml) Absorbance 
0.1 N HCl 6.8pH 
       1                    0 0 0 
       2                    5 0.134 0.127 
       3                   10 0.261 0.245 
       4                   15 0.382 0.388 
       5                   20 0.512 0.523 
       6                   25 0.628 0.641 
 
 
Fig no 1: Calibration curve of Prulifloxacin in 0.1 N HCl 
 
Figure.no:2 Calibration curve of Prulifloxacin in 6.8pH
 
 
Figure.no:3 FTIR of Prulifloxacin 
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Figure.no 4: FTIR of HPMC E15 
 
Figure.no 5: FTIR of HPMC K15  
 
Figure.no 6: FTIR of Best Formulation 
Table 3: Physical properties of blend 
F.CODE 
Angle of 
Repose± SD* 
Bulk Density (g/ml) 
±SD* 
Tapped Density 
(g/ml) ±SD* 
Carr’s Index 
(%)±SD* 
Hausner’s Ratio 
±SD* 
F1 26.25±0.23 0.488±0.0202 0.5091±0.0252 8.61±1.9083 1.0416±0.0088 
F2 27.96±0.15 0.5055±0.0055 0.5170±0.012 8.222±0.2266 1.02227±0.0052 
F3 26.65±0.34 0.4859±0.0069 0.5329±0.0051 8.8235±0.3054 1.0967±0.0321 
F4 28.93±0.12 0.3463±0.068 0.3810±0.0093 9.0909±0.1994 1.1000±0.004 
F5 27.36±0.15 0.3127±0.056 0.3528±0.0009 9.3636±0.6143 1.1082±0.0481 
F6 29.45±0.64 0.4650±0.0019 0.5093±0.001 8.6956±0.1499 1.0952±0.1191 
F7 27.54±0.15 0.5161±0.0050 0.5704±0.0014 9.6774±0.4180 1.1071±0.021 
F8 28.62±0.17 0.5000±0.0007 0.5577±0.0008 9.5750±0.3041 1.1034±0.0071 
F9 28.74±0.25 0.4706±0.0031 0.5333±0.0017 8.7647±0.9171 1.0933±0.0025 
*n = 3 
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Table 4: Evaluation of post compression parameters 
Trial 
Weight variation 
±SD*** 
Thickness 
(mm) ±SD** 
Hardness 
(Kg/cm²) ±SD* 
Friability 
(%w/w) ±SD** 
F1 649±1.422 5.81±0.049 8±0.331 0.32±0.02 
F2 659±2.772 5.84±0.036 8.5±0.338 0.44±0.01 
F3 650±1.631 6.68±0.033 9±0.378 0.37±0.05 
F4 658±1.744 6.04±0.029 9±0.318 0.49±0.03 
F5 657±1.713 5.9±0.027 11±0.347 0.51±0.01 
F6 654±1.313 6.01±0.025 8.5±0.314 0.53±0.05 
F7 659±1.080 5.9±0.027 9.5±0.313 0.54±0.03 
F8 651±1.005 6.1±0.032 10.5±0.383 0.52±0.02 
F9 649±1.426 5.8±0.028 9.5±0.357 0.47±0.05 
*n=6  **n=10 ***n=20 
Table 5: In vitro Drug Release Studies for different Trials Formulations 
Time (hrs.) 
% Cumulative Drug Released ±SD* 
   F 1 F2 F3 F4 F5 F6 F7 F8 F9 
1 27.13± 
0.4676 
23.03± 
0.1869 
18.083± 
0.1329 
12.08± 
0.343 
9.1166± 
0.1834 
83± 
0.4195 
10.1± 
0.2756 
9± 
0.1897 
10.12± 
0.2316 
2 41.96± 
0.4956 
34.03± 
0.1861 
27.06± 
0.1966 
23.083± 
0.2994 
18.13± 
0.2338 
16.2± 
0.3326 
29± 
0.1897 
23.98± 
0.3311 
23.06± 
0.2804 
4 55.966± 
0.1966 
47.01± 
0.1940 
38.95± 
0.4086 
34.1± 
0.5176 
26.95± 
0.3563 
25± 
0.2366 
36.1± 
0.3033 
32.15± 
0.3728 
30.08± 
0.3125 
6 69.2± 
0.129 
58.06± 
0.1972 
46.56± 
1.284 
42.03± 
0.464 
36.58± 
1.099 
32.1± 
0.2581 
49.13± 
0.3771 
38.91± 
0.384 
48.16± 
0.4109 
8 80.96± 
0.1940 
64.16± 
0.1505 
56.85± 
0.4636 
54.11± 
0.3544 
45.1± 
0.2683 
38.86± 
0.4273 
53.13± 
0.388 
45.05± 
1.952 
55.16± 
0.366 
10  82± 
0.1095 
68.13± 
0.2065 
69.18± 
0.4622 
57.2± 
0.2607 
54.18± 
0.2401 
68.98± 
0.2786 
57.06± 
0.3204 
61.1± 
0.2828 
12   78.98± 
0.2786 
77.06± 
0.2804 
68.95± 
0.4549 
62.95± 
0.5890 
75.15± 
0.3146 
64.15± 
0.3016 
76.08± 
0.134 
16   98.08± 
0.240 
86.133± 
0.388 
80.56± 
15.75 
74.11± 
0.285 
83.23± 
0.2338 
79.21± 
0.2857 
82.21± 
0.2857 
20    90.2± 
0.259 
 86.16± 
0.4033 
97.03± 
0.233 
86.05± 
0.288 
87.56± 
0.4844 
24    94.133± 
0.163 
 92± 
0.2756 
 99.08± 
0.183 
93.23± 
0.1966 
*n=6 
        
Fig No.7: In vitro Drug Release Studies for F1, F2, F3     Fig 8: In vitro Drug Release Studies for F4, F5 and F6 
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Fig 9: In vitro Drug Release Studies for F7, F8 andF9 Formulations 
 
Zero Order Plots  
    
Fig 10: Zero order plots of F1-F3      Fig 11: Zero order plots of F4-F6 
 
 
Fig 12: Zero order plots of formulations F7-F9 
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First Order Plots 
     
Fig 13: First order plots of F1-F3                       Fig 14: First order plots of F4-F6 
 
Fig 15: First order plots of formulations F7-F9 
Hixso- Crowell Plots 
   
Fig 16: Hixson Crowell plots of F1-F3                 Fig17: Hixson Crowell plots of F4-F6 
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Fig 18: Hixson Crowell plots of formulations F7-F9 
Higuchi Plots  
    
Fig19: Higuchi plots of F1-F4                         Fig 20: Higuchi plots of F4-F6 
 
 
Fig 21: Higuchi plots of F7-F9 
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Korsmeyer Peppas Plots 
  
Fig22: Korsmeyer Peppas plots of F1-F3          Fig 23: Korsmeyer Peppas plots of F4-F6 
 
 
Fig 24: Korsmeyer Peppas plots of formulations F7-F9 
Table 6: Release Kinetics Studies for different strengths of final optimized formulation 
Formulation 
Code 
R² Values n values 
Zero order First order Hixson Crowell Higuchi Peppas 
F1 0.914 0.079 0.995 0.997 0.509 
F2 0.934 0.146 0.961 0.979 0.517 
F3 0.975 0.053 0.916 0.978 0.595 
F4 0.899 0.088 0.98 0.972 0.582 
F5 0.986 0.002 0.989 0.98 0.794 
F6 0.969 0.04 0.993 0.984 0.758 
F7 0.934 0.073 0.966 0.985 0.691 
F8 0.961 0.155 0.942 0.989 0.573 
F9 0.888 0.061 0.978 0.97 0.655 
 
DISCUSSION OF RESULTS: 
In the present study first characterization of API was done 
followed by its compatibility studies with various excipients 
and API was found to be compatible with all the excipients. 
Then various Pre-compression parameters like bulk density, 
tapped density, Hausner’s ratio, Carr’s consolidation index 
and angle of repose were determined and found to be within 
the limits and post compression parameters like weight 
variation, hardness, friability were determined and found to 
be within limits and In-vitro dissolution of all the 
formulations were analyzed and Among all the nine 
formulations F8 shown maximum drug release of 99.08% 
after 24 hours and all the data were fitted into various 
kinetic models like Zero order, First order, Hixson Crowell, 
Higuchi, Korsmeyer peppas and based on the results obtained 
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from these studies the release was found diffusion controlled 
and followed Zero order kinetics.  
CONCLUSION 
So in this present work an attempt is made to formulate 
sustained release matrix tablet which shown prolonged drug 
release for 24 hours. Prior to the development of dosage 
form, all the fundamental Pre-formulation and Post-
formulation Parameters of drug molecule are evaluated and 
the results were found satisfactory. The formulation was 
characterized for various properties of the dosage forms like 
assay, dissolution and other physical properties. Drug 
release was extended up to 24 hours with diffusion 
controlled and followed Zero order kinetics. Further the 
scope of the work need to be extended to carry out stability 
studies. 
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